JP MORGAN/PUT/VERTEX PHARMACEUTICALS/410/0.1/17.01.25

JP MORGAN/PUT/VERTEX PHARMACEUTICALS/410/0.1/17.01.25 Share Price

DE000JB9ELU5

Real-time Bid/Ask 12:17:25 05/07/2024 BST
1.25 ^EUR / 1.45 ^EUR	+5.47%

1 month	-19.50%
3 months	-67.18%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/PUT/VERTEX PHARMACEUTICALS/410/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
05/07/24	1.21	-5.47%
04/07/24	1.28	+6.67%
03/07/24	1.2	-5.51%
02/07/24	1.27	-4.51%
01/07/24	1.33	+3.91%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 07:29 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JB9ELU
ISIN	DE000JB9ELU5
Date issued	03/01/2024
Strike	410 $
Maturity	17/01/2025 (197 Days)
Parity	10 : 1
Emission price	3.56 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	4.51 €
Lowest since issue	1.2 €
Delta	-0.21x
Omega	6.453
Premium	16.06x
Gearing	30.81x
Moneyness	0.8718
Difference Strike	-60.28 $
Difference Strike %	-14.70%
Spread	0.3 €
Spread %	19.23%
Theoretical value	1.350
Implied Volatility	32.45 %
Total Loss Probability	71.98 %
Intrinsic value	0.000000
Present value	1.350
Break even	395.39 €
Theta	-0.04x
Vega	0.09x
Rho	-0.06x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

470.3 USD

Average target price

468.3 USD

Spread / Average Target

-0.43%

Consensus